These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8197600)

  • 21. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway.
    Uchida N; Shirasugi N; Akiyama Y; Matsumoto K; Shimazu M; Kitajima M; Hamano K; Aramaki O; Ikeda Y; Niimi M
    Transplantation; 2003 Mar; 75(6):878-84. PubMed ID: 12660518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged survival of fetal pig islet xenografts in mice lacking the capacity for an indirect response.
    Koulmanda M; Laufer TM; Auchincloss H; Smith RN
    Xenotransplantation; 2004 Nov; 11(6):525-30. PubMed ID: 15479462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti-CD4 monoclonal antibody.
    Pearson TC; Bushell AR; Darby CR; West LJ; Morris PJ; Wood KJ
    Clin Exp Immunol; 1993 May; 92(2):211-7. PubMed ID: 8097975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged local expression of anti-CD4 antibody by adenovirally transduced allografts can promote long-term graft survival.
    Londrigan SL; Sutherland RM; Brady JL; Zhan Y; Li R; Estella E; Kay TW; Lew AM
    J Gene Med; 2006 Jan; 8(1):42-52. PubMed ID: 16075436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nondepleting anti-CD4 monoclonal antibody enhances the ability of oral alloantigen delivery to induce indefinite survival of cardiac allografts: oral tolerance to alloantigen.
    Niimi M; Witzke O; Bushell A; Hara M; Morris PJ; Wood KJ
    Transplantation; 2000 Nov; 70(10):1524-8. PubMed ID: 11118100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of anti-CD4, anti-NC, and anti-NK monoclonal antibody on the survival of cardiac xenografts and allografts in mice.
    Yang L; Mottram PL; Han WR; Smart YC
    Transplant Proc; 1995 Jun; 27(3):2185-6. PubMed ID: 7792927
    [No Abstract]   [Full Text] [Related]  

  • 27. Current and future application of monoclonal antibodies in clinical immunosuppressive protocols.
    Cosimi AB
    Clin Transplant; 1995 Jun; 9(3 Pt 2):219-26. PubMed ID: 7670167
    [No Abstract]   [Full Text] [Related]  

  • 28. AMIS and antigen modulation: of mice and men.
    Westhoff CM
    Blood; 2016 Dec; 128(26):3026-3028. PubMed ID: 28034869
    [No Abstract]   [Full Text] [Related]  

  • 29. Cool response to report on YTS placements.
    McNally M
    Nurs Stand; 1988 Jan; 2(14):14. PubMed ID: 27414550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac metastases from malignant melanoma.
    Gibbs P; Cebon JS; Calafiore P; Robinson WA
    Cancer; 1999 Jan; 85(1):78-84. PubMed ID: 9921977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A brief spiritual beliefs inventory for use in quality of life research in life-threatening illness.
    Holland JC; Kash KM; Passik S; Gronert MK; Sison A; Lederberg M; Russak SM; Baider L; Fox B
    Psychooncology; 1998; 7(6):460-9. PubMed ID: 9885087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential response of human melanoma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin.
    Poma A; Miranda M; Spanò L
    Melanoma Res; 1998 Oct; 8(5):465-7. PubMed ID: 9835461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clear cell sarcoma of soft tissues. Clinico-pathological and ultrastructural analysis of a case in the head-neck region and a literature review].
    Bisceglia M; Carosi I; Lelli G; Pasquinelli G; Martinelli GN
    Pathologica; 1998 Aug; 90(4):391-6. PubMed ID: 9793401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant neoplastic disease of the parotid lymph nodes.
    Schroeder WA; Stahr WD
    Laryngoscope; 1998 Oct; 108(10):1514-9. PubMed ID: 9778292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PTEN tumour suppressor gene and malignant melanoma.
    Böni R; Vortmeyer AO; Burg G; Hofbauer G; Zhuang Z
    Melanoma Res; 1998 Aug; 8(4):300-2. PubMed ID: 9764804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic node dissections in malignant melanoma.
    Karakousis CP
    Ann Surg Oncol; 1998 Sep; 5(6):473-82. PubMed ID: 9754754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of hepatocyte growth factor/scatter factor on the metastatic phenotype of B16 melanoma cells.
    Rusciano D; Lin S; Lorenzoni P; Casella N; Burger MM
    Tumour Biol; 1998; 19(5):335-45. PubMed ID: 9701724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
    Mordoh J; Kairiyama C; Bover L; Solarolo E
    Medicina (B Aires); 1997; 57(4):421-7. PubMed ID: 9674264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ultraviolet radiation and skin tumors].
    Zanetti R; Tumino R
    Med Lav; 1998; 89(2):142-8. PubMed ID: 9673104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma.
    Sharma D; Chelvi TP; Kaur J; Ralhan R
    Melanoma Res; 1998 Jun; 8(3):240-4. PubMed ID: 9664145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.